Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
差价合约 (CFD) 是一种复杂的金融工具，利用杠杆交易虽然可能放大收益，但同样也会加剧亏损风险，导致资金快速流失。数据显示，82.78% 的散户投资者在使用该提供商服务进行差价合约交易时出现账户亏损。在进行交易之前，请确保您充分了解差价合约的运作机制，并仔细评估自己是否有能力承担资金亏损的高风险。
评分与评论
评分与评论
